Esperion Therapeutics (ESPR) Announces Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at ESC Congress 2018
Tweet Send to a Friend
Esperion (NASDAQ: ESPR) today announced that the final results from the pivotal Phase 3 Study 1 (1002-040 or CLEAR Harmony) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
